Professor Timothy Perren is a consultant medical oncologist specialising in the non-surgical treatment of cancers using chemotherapy, hormonal therapy and the new molecular therapies such as Herceptin (trastuzumab), Perjeta (pertuzumab), Kadcyla (trastuzumab), Tyveb (lapatinib), Avastin (bevacizumab) and Lynparza (olaparib).
Modern treatment for cancer requires the careful integration of diagnostic procedures, surgical treatment and medical therapies.
Treatment is becoming increasingly tailored to the patient and their cancer. Professor Perren believes that it is important to take into account the individual needs and situation of each patient and to involve the patient and their family closely in the development of a treatment plan.
Professor Perren is a member of the multidisciplinary teams for breast cancer and gynaecological cancers at the Leeds Teaching Hospitals NHS Trust and works with the same team of surgeons, radiologists and pathologists in his private practice as he does in the NHS.
Through his NHS practice Professor Perren is involved in many research trials investigating the integration of new treatments into cancer care. He is chief investigator on the influential ICON7 trial published in the New England Journal of Medicine in 2011 which has led to the integration of bevicizumab into standard first treatment for ovarian cancer.
He is also author or co-author in more than a 100 other research papers and abstracts. His current publication profile can be viewed at http://www.researchgate.net/profile/Timothy_Perren
In April 2015 his RG score (calculated based on the publication profile and how other researchers interact with it) within ResearchGate was 40.90 which is higher than 97.5% of ResearchGate members.
He is regularly approached to present his work at International meetings.
Professor Perren trained in general medicine in London and in Stoke on Trent; and is a fellow of the Royal College of Physicians. His oncology training was in Birmingham and at the Royal Marsden Hospital. His MD thesis was concerned with the identification of prognostic factors in breast cancer.
He was appointed consultant medical oncologist at St James's Hospital in Leeds in January 1990 and to the Chair of Women’s Cancers and Oncology in 2013.
Professor Perren specialises in the treatment of breast cancer and gynaecological cancers. He provides treatment for newly diagnosed patients, as well as for those with recurrent or metastatic disease.